Muscat: The Ministry of Health, represented by the Drug Safety Centre, has issued an alert on a rare side effect of GLP-1 medicines that may affect eye health.
The alert, issued with reference to the Centre's circulars No. 165/2025 and 26/2026, follows an update issued by the US Food and Drug Administration (FDA) on 9 November 2026. It states that the use of GLP-1 medicines and tirzepatide may be associated with an increased risk of a rare disorder of the optic nerve known as non-arteritic anterior ischemic optic neuropathy (NAION).
NAION is a rare condition caused by reduced blood flow to the front of the optic nerve. It can cause sudden, painless vision loss in one eye, which may be permanent.
The medicines concerned are used to treat type 2 diabetes. They are also used, under medical supervision and in line with the approved indications for each product, to control weight in people with obesity or overweight accompanied by related health problems.
The medicines named in the update include:
- Semaglutide: Ozempic, Rybelsus, Wegovy
- Liraglutide: Saxenda, Victoza
- Dulaglutide: Trulicity
- Tirzepatide: Mounjaro
The Ministry urged patients to watch for any sudden changes in vision and to seek urgent medical care if they occur, including sudden loss of vision, sudden blurred vision, a blind spot, or a change in colour vision, even in the absence of eye pain.
Patients should not stop treatment or change the dose without consulting their treating physician, the Ministry stressed.
The Ministry also emphasised the importance of the safe use of medicines in accordance with medical instructions, and the need to report any suspected side effects, in order to protect public safety.
Suspected side effects can be reported via the Ministry of Health website - Drug Safety Centre - Pharmacovigilance Department.